Sanofi-Synthelabo expects 15% growth

The Romanian subsidiary of pharmaceutical company Sanofi-Synthelabo estimates to see at least 15% sales growth this year, to 15-20 million euros, in line with the international development strategy of the parent company.

“Sanofi-Synthelabo last year saw sales grow by 32% in Romania, which is one of the highest rates on the market, and concluded the year with 14 million euros. We intend to comply with the international strategy in 2004 and progress by 15-20%,” Dan Ivan, the company’s general manager said.

He added this year would come with a series of changes in the health care system, which would obviously impact on the company’s development.

These factors include, as specified by Ivan, the modifications related to the national programmes and to the lists of subsidised drugs, as well as the release by his company of new indications for its products. ZF